These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 35863460)

  • 21. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.
    Hansen CB; Jarlhelt I; Hasselbalch RB; Hamm SR; Fogh K; Pries-Heje MM; Møller DL; Heftdal LD; Pérez-Alós L; Sørensen E; Larsen MAH; Skjoedt MO; Ostrowski SR; Frikke-Schmidt R; Bayarri-Olmos R; Hilsted LM; Bundgaard H; Nielsen SD; Iversen KK; Garred P
    J Intern Med; 2021 Dec; 290(6):1272-1274. PubMed ID: 34237190
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of Maternal and Neonatal Antibody Levels After COVID-19 Vaccination vs SARS-CoV-2 Infection.
    Flannery DD; Gouma S; Dhudasia MB; Mukhopadhyay S; Pfeifer MR; Woodford EC; Briker SM; Triebwasser JE; Gerber JS; Morris JS; Weirick ME; McAllister CM; Hensley SE; Puopolo KM
    JAMA Netw Open; 2022 Nov; 5(11):e2240993. PubMed ID: 36350652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-SARS-CoV-2 antibodies in breast milk during lactation after infection or vaccination: A cohort study.
    Olearo F; Radmanesh LS; Felber N; von Possel R; Emmerich P; Pekarek N; Pfefferle S; Nörz D; Hansen G; Diemert A; Aepfelbacher M; Hecher K; Lütgehetmann M; Arck PC; Tallarek AC
    J Reprod Immunol; 2022 Sep; 153():103685. PubMed ID: 36029724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SARS-CoV-2 antibody assay after vaccination: one size does not fit all.
    Plebani M; Cosma C; Padoan A
    Clin Chem Lab Med; 2021 Sep; 59(10):e380-e381. PubMed ID: 34187101
    [No Abstract]   [Full Text] [Related]  

  • 25. SARS-CoV-2 spike IgG titres up to 137 days following Comirnaty mRNA COVID-19 vaccination, Israel, February to May 2021.
    Patalon T; Ben Moshe S; Peretz A; Neuberger A; Schreiber L; Lazar R; Supino-Rosin L; Perez G; Mizrahi-Reuveni M; Gazit S
    Euro Surveill; 2022 Oct; 27(40):. PubMed ID: 36205168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis.
    Pellicano C; Campagna R; Oliva A; Leodori G; Miglionico M; Colalillo A; Mezzaroma I; Mastroianni CM; Turriziani O; Rosato E
    Clin Rheumatol; 2022 Sep; 41(9):2755-2763. PubMed ID: 35614287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal vaccination - a case report.
    Paul G; Chad R
    BMC Pediatr; 2021 Mar; 21(1):138. PubMed ID: 33752624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
    Nickel O; Rockstroh A; Wolf J; Landgraf S; Kalbitz S; Kellner N; Borte M; Pietsch C; Fertey J; Lübbert C; Ulbert S; Borte S
    PLoS One; 2022; 17(10):e0263861. PubMed ID: 36256664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review.
    Notarte KI; Guerrero-Arguero I; Velasco JV; Ver AT; Santos de Oliveira MH; Catahay JA; Khan MSR; Pastrana A; Juszczyk G; Torrelles JB; Lippi G; Martinez-Sobrido L; Henry BM
    J Med Virol; 2022 Jul; 94(7):2939-2961. PubMed ID: 35229324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 Antibodies in Breast Milk After Vaccination.
    Romero Ramírez DS; Lara Pérez MM; Carretero Pérez M; Suárez Hernández MI; Martín Pulido S; Pera Villacampa L; Fernández Vilar AM; Rivero Falero M; González Carretero P; Reyes Millán B; Roper S; García Bello MÁ
    Pediatrics; 2021 Nov; 148(5):. PubMed ID: 34408089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects.
    Haveri A; Solastie A; Ekström N; Österlund P; Nohynek H; Nieminen T; Palmu AA; Melin M
    Eur J Immunol; 2022 May; 52(5):816-824. PubMed ID: 35312186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.
    Gobbi F; Buonfrate D; Moro L; Rodari P; Piubelli C; Caldrer S; Riccetti S; Sinigaglia A; Barzon L
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33807957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
    Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
    Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
    Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
    Front Immunol; 2021; 12():737083. PubMed ID: 34539673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.
    Corma-Gómez A; Fernández-Fuertes M; García E; Fuentes-López A; Gómez-Ayerbe C; Rivero-Juárez A; Domínguez C; Santos M; Viñuela L; Palacios R; Real LM; Rivero A; Macías J; Pineda JA; García F
    Clin Microbiol Infect; 2022 Nov; 28(11):1492-1498. PubMed ID: 35640840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pronounced antibody elevation after SARS-CoV-2 BNT162b2 mRNA booster vaccination in nursing home residents.
    Chong Y; Goto T; Tani N; Yonekawa A; Ikematsu H; Shimono N; Tanaka Y; Akashi K
    Influenza Other Respir Viruses; 2022 Nov; 16(6):1066-1071. PubMed ID: 35962568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history.
    McDade TW; Demonbreun AR; Sancilio A; Mustanski B; D'Aquila RT; McNally EM
    Sci Rep; 2021 Aug; 11(1):17325. PubMed ID: 34462501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of antibody response following the vaccination of SARS-CoV-2 infected and noninfected healthcare workers by two-dose inactive vaccine against COVID-19.
    Dundar B; Karahangil K; Elgormus CS; Topsakal HNH
    J Med Virol; 2022 Jun; 94(6):2431-2437. PubMed ID: 35128700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities.
    Trigueros M; Pradenas E; Palacín D; Muñoz-López F; Ávila-Nieto C; Trinité B; Bonet-Simó JM; Isnard M; Moreno N; Marfil S; Rovirosa C; Puig T; Grau E; Chamorro A; Martinez A; Toledo R; Font M; Ara J; Carrillo J; Mateu L; Blanco J; Clotet B; Prat N; Massanella M;
    Age Ageing; 2022 May; 51(5):. PubMed ID: 35595256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
    Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
    Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.